Abstract
Male and female Sprague Dawley rats were injected intraperitoneally for 4 weeks with ammonium trichloro (dioxyethylene-0-0′-) tellurate, an immunomodulating drug at closes ranging from 3 to 24 mg/kg/week. Routine laboratory examinations included body weight, food consumption, clinical chemistry and hematological examinations. At termination of the experiment, all rats were sacrificed and subjected to a detailed necropsy. Few mortalities were recorded during the course of the study. Clinical signs included hind limb paresis and paraphimosis. A garlic odor pervaded the room. Body weight and food consumption were adversely affected in a dose-related manner. Effects were elicited on the hematological system; changes being noted in the platelet and leukocyte counts as well. Clinical chemistry evaluation revealed signs of hepatoxicity, especially in the female treated groups. The level of beta-globulin was increased. At necropsy organs were found to have a grayish-blue discoloration. Tellurium related histopathological changes were observed in the eyes, liver, thymus, bone marrow, heart and kidneys. An attempt has been made to compare the toxicity of this drug with other tellurium-containing compounds. A good correlation was found. Novel effects of the drug were retinopathy and replacement of bone marrow by bony or fibrous tissue. The possibility that some of the effects may have been elicited due to selenium-vitamin E deficiency has been considered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bouldin TW, Sansa G, Earnhardt TS, Krigman MR (1988) Schwann cell vulnerability to demyelination is associated with internodal length in tellurium neuropathy. J Neuropathol Exp Neurol 4: 41–47
Carlton WW, Kelly WA (1967) Tellurium toxicosis in Pekin ducks. Toxicol Appl Pharmacol 11: 203–214
Cerwenka EA, Cooper WC (1961) Toxicology of selenium and tellurium and their compounds. Arch Environ Hlth 3: 189–200
DeMeio RH (1946) Tellurium I. The toxicity of elementry tellurium for rats and rat tissues. J Ind Hyg Toxicol 28: 229–232
DeMeio RH, Jetter WW (1984) Tellurium III. The toxicity of ingested tellurium dioxide for rats. J Ind Hyg Toxicol 30: 53–58
Duckett S, Said G, Streletz LG, White RG, Galle P (1979) Tellurium-induced neuropathy. Correlative physiological morphological and electron microprobe studies. Neuropathol Appl Neurobiol 5: 265–278
Hammeng JP, Duncan ID, Galmere SA (1986) Degenerative changes in rat intraspinal Schwann cells following tellurium intoxication. Neuropathol Appl Neurobiol 12: 339–370
Klevay LM (1976) Pharmacology and toxicology of heavy metals: tellurium. Pharmacol Ther 1: 223–229
Laporte GP, Frottier G, Lebas G, Dormont D, Meyohas MC, Eliaszewicz M, Gonzales G, Dubeaux D, Prugnaud GL, Sredni B, Albeck M (1988) A new immunodulating compound (AS-101) in the treatment of AIDS. IV International Conference on AIDS, Stockholm, Sweden, p 229
Malya PAG (1984) Role of clinical pathology in the preclinical assessment of drugs and chemicals. In: Concepts in Toxicology. Karger, Basel, pp 213–227
Meier-Ruge W (1972) Drug induced retinopathy. CRC Crit Rev Toxicol 3: 325–360
Nyska A, Bor Ishak Yr, Ashkenazy D, Friedman J, Kashman J, Lelyveld J, (1984) Retinol atrophy in albino rats associated with Pituranthos triradiatus (Umbelliferae) — Induced photosensitization. Vet Pathol 21: 551–552
Phillips MJ, Poucell S, Patterson J, Valencia P (1987) The liver. An atlas and text of ultrastructural pathology. Raven Press, New York, p 169
Riis RC, Sheffy BE, Loew E, Kern TJ, Smith JS (1981) Vitamin E deficiency retinopathy in dogs. Am J Vet Res 42: 74–86
Ruiz-Palacios GM, Ponce de Leon S, Alarcon-Segovia D, Alcocer Varela J, Cruz A, Nares F, Ponce de leon A, Rojas G, Sredni B (1988) Tolerance evaluation and clinical response to a novel immunomodulator AS-101, in patients with AIDS. IV International Conference on AIDS, Stockholm, Sweden, p 229
Sandratskaya SE (1967) Tellurium. In: Israelson ZI (ed) Toxicology of the rare metals. Clearing House for Federal Scientific and Technical Information. Springfield, Va., pp 76–88
Sokal RR, Rolhlf FJ (1981) Biometry, 2nd edn. W. H. Freeman and Company, New York, pp 402–412
Sredni B, Caspi RR, Klein A, Kalechman Y, Danziger Y, Ben Ya'akov M, Tamari T, Shalit F, Albeck M (1987) A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 330: 173–176
Sredni B, Caspi RR, Lustig S, Klein A, Kalechman Y, Danziger Y, Ben Ya'akov M, Tamari T, Shalit F, Albeck M (1988a) The biological activity and immunotherapeutic properties of AS-101, a synthetic organotellurium compound. Nat Immun Cell Growth Reg 7: 163–168
Sredni B, Caspi RR, Klein A, Shani R, Catane R, Tichier T, Michlin H, Tamari T, Shalit F, Albeck M (1988b) Immunotherapeutic properties of AS-101. A synthetic organotellurium compound. IV International Conference on AIDS, Stockholm, Sweden, p 229
Tardach C, Greaves P (1984) Spontaneous eye lesions in laboratory animals: Incidence in relation to age. CRC Crit Rev Toxicol 12: 121–147
Van Vleet JF, Ferrans VJ (1982) Myocardial ultrastructural alterations in ducklings fed tellurium. Am J Vet Res 43: 2000–2009
Van Vleet JF, Boon GD, Ferrans VJ (1981) Induction of lesions of selenium-vitamin E deficiency in weanling swine fed sliver, cobalt, tellurium, zinc, cadmium and vanadium. Am J Vet Res 42: 789–799
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nyska, A., Waner, T., Pirak, M. et al. Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: A potential drug for AIDS and cancer patients. Arch Toxicol 63, 386–393 (1989). https://doi.org/10.1007/BF00303128
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00303128